Abstract: The present disclosure generally relates to genetic methods of manipulating helminths, e.g., hookworms, to act as a biological delivery vehicle for therapeutic polypeptides in mammals. Furthermore, the disclosure is drawn to compositions comprising genetically modified hookworms and methods of use, including the administration of the helminths to one or more mammals to provide a continuous supply of a synthetic or modified polypeptide (e.g., HIV neutralizing antibodies) which may mitigate infection and/or infection intensity, otherwise resulting in an increase in a desirable phenotypic trait.

Abstract: A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens are Necator americanus antigens, although antigens from other hookworm species (e.g. Ancylostoma duodenale) may also be employed. The schistosome antigen is preferably a Schistosoma mansoni or a Schistosoma haematobium antigen although antigens from other schistosome species (e.g. Schistosoma japonicum) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {Necator americanus) to produce recombinant chimeric antigens.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens are Necator americanus antigens, although antigens from other hookworm species (e.g. Ancylostoma duodenale) may also be employed. The schistosome antigen is preferably a Schistosoma mansoni or a Schistosoma haematobium antigen although antigens from other schistosome species (e.g. Schistosoma japonicum) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {Necator americanus) to produce recombinant chimeric antigens.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: Preparations which elicit an immune response to hookworm antigens and which may be utilized as hookworm vaccines are provided. In addition, a method of increasing the effectiveness of vaccinations against infectious diseases in patients infected with hookworm is provided. The method involves chemically treating the hookworm infestation prior to administering the vaccine.

Abstract: Preparations which elicit an immune response to hookworm antigens and which may be utilized as hookworm vaccines are provided. In addition, a method of increasing the effectiveness of vaccinations against infectious diseases in patients infected with hookworm is provided. The method involves chemically treating the hookworm infestation prior to administering the vaccine.